FNCH

Finch Therapeutics Group Inc

FNCH, USA

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

https://www.finchtherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FNCH
stock
FNCH

Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.9% – Should You Sell? Defense World

Read more →
FNCH
stock
FNCH

What Makes Finch Therapeutics (FNCH) a Worthy Investment? Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-06-30)

Rating:

BUY

Target Price:

$90

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-06-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.53

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-34.00 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.61 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.21

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 9.99% of the total shares of Finch Therapeutics Group Inc

1.

Susquehanna International Group, LLP

(3.676%)

since

2023/12/31

2.

Vanguard Group Inc

(2.2576%)

since

2024/03/31

3.

Vanguard Institutional Extnd Mkt Idx Tr

(1.011%)

since

2024/04/30

4.

Renaissance Technologies Corp

(0.7315%)

since

2023/12/31

5.

Vanguard Total Stock Mkt Idx Inv

(0.6045%)

since

2024/04/30

6.

Greenwich Ivy Long-Short Instl

(0.4669%)

since

2023/12/31

7.

Ikarian Capital, LLC

(0.4292%)

since

2024/03/31

8.

Fidelity Extended Market Index

(0.2312%)

since

2024/03/31

9.

Tower Research Capital LLC

(0.1635%)

since

2023/12/31

10.

Fidelity Total Market Index

(0.1001%)

since

2024/03/31

11.

Bleichroeder LP

(0.0605%)

since

2024/03/31

12.

Fidelity Nasdaq Composite Index

(0.0529%)

since

2024/03/31

13.

Northern Trust Extended Eq Market Idx

(0.0356%)

since

2024/03/31

14.

NT Ext Equity Mkt Idx Fd - L

(0.0356%)

since

2024/03/31

15.

Spartan Total Market Index Pool E

(0.0301%)

since

2024/03/31

16.

BlackRock Inc

(0.0212%)

since

2023/12/31

17.

NT Ext Equity Mkt Idx Fd - NL

(0.0149%)

since

2024/03/31

18.

Fidelity Series Total Market Index

(0.0145%)

since

2024/03/31

19.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.012%)

since

2023/12/31

20.

Northwestern Mutual Wealth Management Co

(0.0088%)

since

2023/12/31

21.

Morgan Stanley - Brokerage Accounts

(0.0077%)

since

2023/12/31

22.

State St US Extended Mkt Indx NL Cl C

(0.0066%)

since

2024/04/30

23.

SSgA U.S. Extended Market Index Class I

(0.0066%)

since

2023/12/31

24.

SSgA U.S. Total Market Index Strategy

(0.0019%)

since

2023/12/31

25.

State St US Ttl Mkt Indx SL Cl I

(0.0019%)

since

2024/04/30

26.

Royal Bank of Canada

(0.0017%)

since

2023/12/31

27.

Northern Trust Wilshire 5000

(0.0017%)

since

2024/03/31

28.

NT US Market Cap Idx Fd - L

(0.0017%)

since

2023/12/31

29.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0014%)

since

2024/03/31

30.

BlackRock Extended Mkt Composite

(0.0009%)

since

2023/09/30

31.

Bank of America Corp

(0.0007%)

since

2023/12/31

32.

Wells Fargo & Co

(0.0004%)

since

2023/12/31

33.

Moisand Fitzgerald Tamayo, LLC

(0.0002%)

since

2023/12/31

34.

Cutler Group LP

(0.0002%)

since

2023/12/31

35.

UBS Group AG

(0.0001%)

since

2023/12/31

36.

MSD Partners, L.P.

(0%)

since

2023/12/31

37.

LAKE STREET ADVISORS GROUP, LLC

(0%)

since

2023/12/31

38.

Ancora Advisors LLC

(0%)

since

2023/12/31

40.

Baupost Group LLC

(0%)

since

2024/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-06-30

EPS Actual

-3.01

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2024-06-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1)
Value
Overpriced(3)

Income Statement

(Last Updated 2024-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.